{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:44:49Z","timestamp":1793781889309,"version":"4.6.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s10620-019-05492-y","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T08:58:33Z","timestamp":1549529913000},"page":"1945-1951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Real-World Experience with Tofacitinib in IBD at a Tertiary Center"],"prefix":"10.1007","volume":"64","author":[{"given":"Roni","family":"Weisshof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Aharoni Golan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip H.","family":"Sossenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"El Jurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E.","family":"Ollech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Pekow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushila","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"5492_CR1","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","volume":"65","author":"JM Dahlhamer","year":"2016","unstructured":"Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged\u2009>\/=18 years\u2014United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:1166\u20131169.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"5492_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46\u201354 (quiz e30).","journal-title":"Gastroenterology"},{"key":"5492_CR3","doi-asserted-by":"publisher","first-page":"j2505","DOI":"10.1136\/bmj.j2505","volume":"357","author":"BL Cohen","year":"2017","unstructured":"Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505.","journal-title":"BMJ"},{"key":"5492_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/ajg.2011.73","volume":"106","author":"AC Ford","year":"2011","unstructured":"Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644\u2013659 (quiz 660).","journal-title":"Am J Gastroenterol"},{"key":"5492_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/apt.14167","volume":"46","author":"A Amiot","year":"2017","unstructured":"Amiot A, Serrero M, Peyrin-Biroulet L, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46:310\u2013321.","journal-title":"Aliment Pharmacol Ther"},{"key":"5492_CR6","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:318\u2013328.","journal-title":"Clin Exp Rheumatol"},{"key":"5492_CR7","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1053\/j.gastro.2016.10.018","volume":"152","author":"C Abraham","year":"2017","unstructured":"Abraham C, Dulai PS, Vermeire S, Sandborn WJ. Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology. 2017;152:e374.","journal-title":"Gastroenterology"},{"key":"5492_CR8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u20131736.","journal-title":"N Engl J Med"},{"key":"5492_CR9","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:e251\u2013e253.","journal-title":"Gastroenterology"},{"key":"5492_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"5492_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/1744666X.2017.1291342","volume":"13","author":"P Olivera","year":"2017","unstructured":"Olivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in inflammatory bowel disease. Expert Rev Clin Immunol. 2017;13:693\u2013703.","journal-title":"Expert Rev Clin Immunol"},{"key":"5492_CR12","doi-asserted-by":"publisher","first-page":"e1482","DOI":"10.1016\/j.cgh.2014.01.029","volume":"12","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014;12:e1482.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5492_CR13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Panes","year":"2017","unstructured":"Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66:1049\u20131059.","journal-title":"Gut"},{"key":"5492_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266\u2013275.","journal-title":"Lancet"},{"key":"5492_CR15","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1002\/art.38779","volume":"66","author":"S Cohen","year":"2014","unstructured":"Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2924\u20132937.","journal-title":"Arthritis Rheumatol"},{"key":"5492_CR16","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675\u20132684.","journal-title":"Arthritis Rheumatol"},{"key":"5492_CR17","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ibd\/izy131","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258\u20132265.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-05492-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05492-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05492-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T19:14:34Z","timestamp":1581016474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-05492-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["5492"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05492-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"12 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"RW, MAG, KEJ, and PHS have no relevant disclosures. DTR is a consultant and has received grant support from Abbvie, Abgenomics, Allergan Inc, Ferring Pharmaceuticals, Genentech\/Roche, Janssen Pharmaceuticals, Merck & Co Inc., Medtronic, Napo Pharmaceuticals, Takeda, Pfizer, Shire and Target Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}